201
|
Abstract
Invasive yeast infections are a significant cause of morbidity and mortality in patients with defective immune response, such as those with cancer-related immunosuppression, organ transplantation or other immunodeficiencies, and neonates. Hospitalization in the intensive care unit may increase the risk for such infections. Despite the advent of new antifungal agents, the problem is escalating as the number of susceptible hosts increase and virulent, more resistant fungal strains emerge. Over the past few years, advances in immunology and molecular biology have greatly contributed to a better understanding of the pathogenesis of yeast infections. There is evidence that reconstitution of the host immune function is a major contributor to the resolution of yeast infections. Strategies aiming to increase the phagocyte number (e.g., granulocyte transfusions), to stimulate immune response (e.g., administration of hematopoietic growth factors and other proinflammatory cytokines) and to stimulate antigen-specific immunity (e.g., antibody therapy or vaccination) benefit patients at risk of, or suffering from, yeast infections. Further preclinical and clinical studies, as well as improving our understanding of immune system functions and dysfunctions, remain a future challenge.
Collapse
Affiliation(s)
- Jorge Garbino
- University Hospitals of Geneva, Infectious Diseases Division (Clinical Research), 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland.
| | | | | |
Collapse
|
202
|
Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2014; 2:357-66. [PMID: 15482201 DOI: 10.1586/14787210.2.3.357] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Candidia spp. are responsible for contributing to the increasing global prevalence of fungal infections. Fluconazole (Diflucan((R)), Pfizer) is a triazole that has established an exceptional therapeutic record for candida infections including oropharyngeal and esophageal candidiasis, vulvovaginal candidiasis, candidemia and disseminated candidiasis. It is both an oral and parenteral fungistatic agent that inhibits ergosterol synthesis in yeasts. Extensive clinical studies have demonstrated fluconazole's remarkable efficacy, favorable pharmacokinetics and reassuring safety profile, all of which have contributed to its widespread use. Fluconazole became the first antifungal with worldwide sales exceeding billions of dollars, therefore providing an incentive for the pharmaceutical industry to develop new antifungals. This review will examine the contributions and limitations of fluconazole in the treatment of superficial and invasive candidiasis syndromes.
Collapse
Affiliation(s)
- Raymond Cha
- Eugene Applebaum College of Pharmacy and Health Sciences, School of Medicine, AntiInfective Research Laboratory, Wayne State University, Detroit, Michigan 48201, USA.
| | | |
Collapse
|
203
|
Abstract
Candiduria is a nonspecific finding that occurs with contamination of a urine sample, colonization of an indwelling catheter and/or the bladder, symptomatic cystitis and invasive upper tract infection. Most patients are colonized and do not require antifungal therapy. Removing predisposing factors, such as indwelling catheters and antibiotics, will clear candiduria in almost 50% of asymptomatic patients. For patients with symptomatic Candida urinary tract infections, a variety of treatment options are available. Fluconazole is the antifungal agent of choice, achieving high urine concentrations with the oral formulation. Rarely, amphotericin B or flucytosine are used. Newer azole agents and echinocandins are not recommended for the treatment of urinary tract infections since they fail to achieve adequate urine concentrations.
Collapse
Affiliation(s)
- Anurag N Malani
- Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System, Internal Medicine, University of Michigan Health System, 2215 Fuller Road, Ann Arbor, MI 48105, USA.
| | | |
Collapse
|
204
|
Deck DH, Guglielmo BJ. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti Infect Ther 2014; 4:137-49. [PMID: 16441215 DOI: 10.1586/14787210.4.1.137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Invasive candidiasis is a common nosocomial infection, especially among the critically ill and immunocompromised patient populations. The recent standardization and increasing availability of antifungal susceptibility testing has the potential to optimize the selection of antifungal therapy. Treatment has been revolutionized in recent years with the marketing of several antifungal agents with excellent activity against Candida spp. These agents include the triazoles, fluconazole and voriconazole, and the echinocandin antifungals. While more expensive by acquisition cost, these newer agents are less toxic than the previously used drugs, and the triazoles offer the additional benefit of oral administration. The availability of new agents, future adoption of diagnostic tests for candidiasis, and susceptibility testing will have a major impact in the management of invasive candidiasis.
Collapse
Affiliation(s)
- Daniel H Deck
- San Francisco General Hospital, San Francisco, CA, USA.
| | | |
Collapse
|
205
|
|
206
|
Kato K, Onoda S, Asano J, Fukaya S, Yoshida S. Evaluation of the clinical cutoff level of serum (1 → 3)-β-d-glucan in patients with connective tissue diseases complicated by deep fungal infections. Mod Rheumatol 2014. [DOI: 10.3109/s10165-010-0287-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
207
|
Chan KM, Gomersall CD. Pneumonia. OH'S INTENSIVE CARE MANUAL 2014. [PMCID: PMC7310946 DOI: 10.1016/b978-0-7020-4762-6.00036-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
208
|
Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract 2014; 68:20-7. [PMID: 24341299 DOI: 10.1111/ijcp.12231] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Accepted: 06/07/2013] [Indexed: 11/29/2022] Open
Abstract
AIMS Echinocandins are recommended for the treatment of candidaemia in moderately severe to severely ill patients. Step-down or de-escalation from echinocandin to fluconazole is advised in patients who are clinically stable but data in relation to step-down therapy are sparse. Using our hospital intravenous to oral switch therapy (IVOST) policy to guide antifungal de-escalation in patients with candidaemia, we aimed to determine what proportion of patients are de-escalated to fluconazole, the timescale to step-down, associated reduction in consumption of echinocandins and antifungal cost savings. METHODOLOGY Patients with candidaemia were followed from April 2011 to March 2013. RESULTS A total of 37 episodes of candidaemia were documented during the study period. Twenty-seven patients were commenced on an echinocandin or voriconazole and 19 (70.3%) were de-escalated to fluconazole based on the IVOST policy. The mean and median number of days to de-escalation of therapy was 4.6 and 5 days, respectively. One patient whose therapy was de-escalated relapsed. The overall 30 day crude mortality was 37.1%. The step-down approach led to significant saving in antifungal drug cost of £1133.88 per candidaemic episode and £2208.08 per de-escalation. CONCLUSION Implementation of IVOST policy led to streamlining of antifungal therapy.
Collapse
Affiliation(s)
- A M Bal
- Department of Microbiology, University Hospital Crosshouse, Kilmarnock, UK
| | | | | | | | | | | |
Collapse
|
209
|
Tissot F, Lamoth F, Hauser PM, Orasch C, Flückiger U, Siegemund M, Zimmerli S, Calandra T, Bille J, Eggimann P, Marchetti O. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188:1100-9. [PMID: 23782027 DOI: 10.1164/rccm.201211-2069oc] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
RATIONALE Life-threatening intraabdominal candidiasis (IAC) occurs in 30 to 40% of high-risk surgical intensive care unit (ICU) patients. Although early IAC diagnosis is crucial, blood cultures are negative, and the role of Candida score/colonization indexes is not established. OBJECTIVES The aim of this prospective Fungal Infection Network of Switzerland (FUNGINOS) cohort study was to assess accuracy of 1,3-β-d-glucan (BG) antigenemia for diagnosis of IAC. METHODS Four hundred thirty-four consecutive adults with abdominal surgery or acute pancreatitis and ICU stay 72 hours or longer were screened: 89 (20.5%) at high risk for IAC were studied (68 recurrent gastrointestinal tract perforation, 21 acute necrotizing pancreatitis). Diagnostic accuracy of serum BG (Fungitell), Candida score, and colonization indexes was compared. MEASUREMENTS AND MAIN RESULTS Fifty-eight of 89 (65%) patients were colonized by Candida; 29 of 89 (33%) presented IAC (27 of 29 with negative blood cultures). Nine hundred twenty-one sera were analyzed (9/patient): median BG was 253 pg/ml (46-9,557) in IAC versus 99 pg/ml (8-440) in colonization (P < 0.01). Sensitivity and specificity of two consecutive BG measurements greater than or equal to 80 pg/ml were 65 and 78%, respectively. In recurrent gastrointestinal tract perforation it was 75 and 77% versus 90 and 38% (Candida score ≥ 3), 79 and 34% (colonization index ≥ 0.5), and 54 and 63% (corrected colonization index ≥ 0.4), respectively. BG positivity anticipated IAC diagnosis (5 d) and antifungal therapy (6 d). Severe sepsis/septic shock and death occurred in 10 of 11 (91%) and 4 of 11 (36%) patients with BG 400 pg/ml or more versus 5 of 18 (28%, P = 0.002) and 1 of 18 (6%, P = 0.05) with BG measurement less than 400 pg/ml. β-Glucan decreased in IAC responding to therapy and increased in nonresponse. CONCLUSIONS BG antigenemia is superior to Candida score and colonization indexes and anticipates diagnosis of blood culture-negative IAC. This proof-of-concept observation in strictly selected high-risk surgical ICU patients deserves investigation of BG-driven preemptive therapy.
Collapse
|
210
|
Ibrahim NH, Melake NA, Somily AM, Zakaria AS, Baddour MM, Mahmoud AZ. The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms. Saudi Pharm J 2013; 23:55-66. [PMID: 25685044 DOI: 10.1016/j.jsps.2013.12.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Accepted: 12/14/2013] [Indexed: 01/11/2023] Open
Abstract
Biofilm formation is often associated with increased Candida resistance toward antifungal agents. Therefore, the current study aimed to assess the incidence of biofilm formation among Candida isolates and to investigate the effect of high doses of fluconazole {FLC}, voriconazole {VOC} and amphotericin B {AMB}, singly and in combination on mature biofilms. Moreover, it aimed to assess the expression of selected genes (CDR1, KRE1 and SKN1) responsible for Candida biofilm resistance. The study included 49 patients; samples were collected from the King Khalid Hospital, Riyadh, Saudi Arabia. Isolates were prepared for biofilm formation and quantification using 0.4% (w/v) crystal violet. Minimum Inhibitory concentration (MIC) and fractional inhibitory concentration (FIC) were conducted by the broth microdilution method. Biofilm eradication was evaluated using counting, XTT stain intensity and observed under the inverted microscope. Selected genes were evaluated in Candida biofilms under the effect of antifungal exposure using QPCR. The major isolates were Candida albicans (65.3%) followed by Candida tropicalis and Candida glabrata. 77.6% of the strains were biofilm formers. AMB showed susceptibility in 87.8% of isolates, followed by VOC (77.6%) and FLC (67.3%). MIC50 and MIC90 were (0.03, 0.125), (0.5, 8), (2, >128) μg/ml for AMB, VOC and FLC, respectively. 34.7% and 18.4% of the isolates were antagonistic to AMB/FLC and AMB/VOC, respectively. Mature biofilms of ten selected isolates were found resistant to FLC (1000 μg/ml). VOR and AMB concentration required to inhibit biofilm formation was 16-250 fold higher than the MIC for planktonic cells. Isolates showed significant reduction with antifungal combination when compared with the untreated controls (p value ⩽ 0.01), or using fluconazole alone (p value ⩽ 0.05). High doses of the antifungals were employed to assess the effect on the persisters' selected gene expression. Marked over expression of SKN1 and to a lesser extent KRE1 was noticed among the mature biofilms treated with AMB alone or in combination after 1 h of exposure, and SKN1 expression was even more sharply induced after 24 h. No statistically significant over expression of CDR1 was observed in biofilms after exposure to high doses of FLC, VOC or any of the combinations used.
Collapse
Affiliation(s)
- Nermin H Ibrahim
- Medical Microbiology and Immunology Department, Faculty of Medicine, Beni Suef University, Egypt ; Pharmaceutics Department, College of Pharmacy, King Saud University, Saudi Arabia
| | - Nahla A Melake
- Medical Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Egypt
| | - Ali M Somily
- Microbiology Department, Faculty of Medicine, King Saud University, Saudi Arabia
| | - Azza S Zakaria
- Pharmaceutics Department, College of Pharmacy, King Saud University, Saudi Arabia ; Microbiology Department, Faculty of Pharmacy, Alexandria University, Egypt
| | - Manal M Baddour
- Medical Microbiology and Immunology Department, Faculty of Medicine, Alexandria University, Egypt
| | - Amany Z Mahmoud
- Pharmaceutics Department, College of Pharmacy, King Saud University, Saudi Arabia ; Pharmaceutical Medicinal Chemistry Department, College of Pharmacy, Assiut University, Egypt
| |
Collapse
|
211
|
Melhem MSC, Bertoletti A, Lucca HRL, Silva RBO, Meneghin FA, Szeszs MW. Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species. Braz J Microbiol 2013; 44:1257-66. [PMID: 24688520 PMCID: PMC3958196 DOI: 10.1590/s1517-83822014005000018] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 09/10/2012] [Indexed: 11/21/2022] Open
Abstract
Eleven quality control isolates (Candida albicans ATCC 64548, C. tropicalis ATCC 200956, C. glabrata ATCC 90030, C. lusitaniae ATCC 200951, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, C. dubliniensis ATCC 6330, Saccharomyces cerevisiae ATCC 9763, Cryptococcus neoformans ATCC 90012, C. gattii FIOCRUZ-CPF 60, and Trichosporon mucoides ATCC 204094) and 32 bloodstream isolates, including C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, C. guilliermondii, C. pelliculosa (Pichia anomala), C. haemulonii, C. lusitaniae, and C. kefyr were identified at the species level by the VITEK 2 system. A set of clinical isolates (32 total) were used as challenge strains to evaluate the ability of the VITEK 2 system to determine the antifungal susceptibility of yeasts compared with the CLSI and EUCAST BMD reference standards. The VITEK 2 system correctly identified 100% of the challenge strains. The identification of yeast species and the evaluation of their susceptibility profiles were performed in an automated manner by the VITEK 2 system after approximately 15 h of growth for most species of Candida. The VITEK 2 system ensures that each test is performed in a standardized manner and provides quantitative MIC results that are reproducible and accurate when compared with the BMD reference methods. This system was able to determine the MICs of amphotericin B, flucytosine, voriconazole, and fluconazole in 15 h or less for the most common clinically relevant Candida species. In addition, the VITEK 2 system could reliably identify resistance to flucytosine, voriconazole, and fluconazole and exhibits excellent quantitative and qualitative agreement with the CLSI or EUCAST broth microdilution reference methods.
Collapse
Affiliation(s)
- MSC Melhem
- Instituto Adolfo Lutz, Secretaria da Saúde, Governo do Estado de São Paulo, São Paulo, SP, Brazil
| | - A Bertoletti
- Instituto Adolfo Lutz, Secretaria da Saúde, Governo do Estado de São Paulo, São Paulo, SP, Brazil
| | - HRL Lucca
- Instituto Adolfo Lutz, Secretaria da Saúde, Governo do Estado de São Paulo, São Paulo, SP, Brazil
| | | | - FA Meneghin
- Instituto Adolfo Lutz, Secretaria da Saúde, Governo do Estado de São Paulo, São Paulo, SP, Brazil
| | - MW Szeszs
- Instituto Adolfo Lutz, Secretaria da Saúde, Governo do Estado de São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
212
|
Zhao LX, Li DD, Hu DD, Hu GH, Yan L, Wang Y, Jiang YY. Effect of tetrandrine against Candida albicans biofilms. PLoS One 2013; 8:e79671. [PMID: 24260276 PMCID: PMC3832530 DOI: 10.1371/journal.pone.0079671] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Accepted: 09/25/2013] [Indexed: 02/07/2023] Open
Abstract
Candida albicans is the most common human fungal pathogen and has a high propensity to develop biofilms that are resistant to traditional antifungal agents. In this study, we investigated the effect of tetrandrine (TET) on growth, biofilm formation and yeast-to-hypha transition of C. albicans. We characterized the inhibitory effect of TET on hyphal growth and addressed its possible mechanism of action. Treatment of TET at a low concentration without affecting fungal growth inhibited hyphal growth in both liquid and solid Spider media. Real-time RT-PCR revealed that TET down-regulated the expression of hypha-specific genes ECE1, ALS3 and HWP1, and abrogated the induction of EFG1 and RAS1, regulators of hyphal growth. Addition of cAMP restored the normal phenotype of the SC5314 strain. These results indicate that TET may inhibit hyphal growth through the Ras1p-cAMP-PKA pathway. In vivo, at a range of concentrations from 4 mg/L to 32 mg/L, TET prolonged the survival of C. albicans-infected Caenorhabditis elegans significantly. This study provides useful information for the development of new strategies to reduce the incidence of C. albicans biofilm-associated infections.
Collapse
Affiliation(s)
- Lan-Xue Zhao
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
- Department of Pharmacy, Institute of Medical Sciences, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - De-Dong Li
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
| | - Dan-Dan Hu
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
| | - Gan-Hai Hu
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
- Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China
| | - Lan Yan
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
| | - Yan Wang
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
- * E-mail: (YW); (YYJ)
| | - Yuan-Ying Jiang
- New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai, China
- * E-mail: (YW); (YYJ)
| |
Collapse
|
213
|
Hwang SY, Yu SJ, Lee JH, Kim JS, Yoon JW, Kim YJ, Yoon JH, Kim EC, Lee HS. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis 2013; 33:259-64. [DOI: 10.1007/s10096-013-1953-2] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 08/06/2013] [Indexed: 02/06/2023]
|
214
|
Kali A, Charles MP, Noyal MJ, Sivaraman U, Kumar S, Easow JM. Prevalence of Candida co-infection in patients with pulmonary tuberculosis. Australas Med J 2013; 6:387-91. [PMID: 24039631 DOI: 10.4066/amj.2013.1709] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Candida species are emerging as a potentially pathogenic fungus in patients with broncho-pulmonary diseases. The synergistic growth promoting association of Candida and Mycobacterium tuberculosis has raised increased concern for studying the various Candida spp . and its significance in pulmonary tuberculosis patients during current years. AIMS This study was undertaken with the objective of discovering the prevalence of co-infection caused by different Candida species in patients with pulmonary tuberculosis. METHOD A total of 75 patients with pulmonary tuberculosis diagnosed by sputum Ziehl-Neelsen staining were included in the study. Candida co-infection was confirmed using the Kahanpaa et al. criteria. Candida species were identified using gram stain morphology, germ tube formation, morphology on cornmeal agar with Tween-80, sugar fermentation tests and HiCrome Candida Agar. RESULTS Candida co-infection was observed in 30 (40%) of patients with pulmonary tuberculosis. Candida albicans was the most common isolate observed in 50% of the patients with co-infection, followed by C. tropicalis (20%) and C. glabrata (20%). Candida co-infection was found in 62.5% of female patients, while it was observed in only 29.4% of the male patients (P value 0.0133). Mean ± SD age of the patients with C. glabrata infection was 65.83 ± 3.19, while the mean ± SD age of the patients with other Candida infections was 43.25 ± 20.44 (P value 0.0138). CONCLUSION Many patients with pulmonary tuberculosis have co-infection with Candida spp. The prevalence of non-albicans Candida species is increasing and may be associated with inadequate response to anti-tubercular drugs. C. glabrata infection has a strong association with old age.
Collapse
Affiliation(s)
- Arunava Kali
- Department of Microbiology, Mahatma Gandhi Medical College & Research Institute, Pondicherry
| | | | | | | | | | | |
Collapse
|
215
|
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob Agents Chemother 2013; 57:4999-5004. [PMID: 23896473 DOI: 10.1128/aac.00707-13] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Invasive aspergillosis and candidemia are important causes of morbidity and mortality in immunocompromised and critically ill patients. The triazoles voriconazole, fluconazole, and posaconazole are widely used for the treatment and prophylaxis of these fungal infections. Due to the variability of the pharmacokinetics of the triazoles among and within individual patients, therapeutic drug monitoring is important for optimizing the efficacy and safety of antifungal treatment. A dried blood spot (DBS) analysis was developed and was clinically validated for voriconazole, fluconazole, and posaconazole in 28 patients. Furthermore, a questionnaire was administered to evaluate the patients' opinions of the sampling method. The DBS analytical method showed linearity over the concentration range measured for all triazoles. Results for accuracy and precision were within accepted ranges; samples were stable at room temperature for at least 12 days; and different hematocrit values and blood spot volumes had no significant influence. The ratio of the drug concentration in DBS samples to that in plasma was 1.0 for voriconazole and fluconazole and 0.9 for posaconazole. Sixty percent of the patients preferred DBS analysis as a sampling method; 15% preferred venous blood sampling; and 25% had no preferred method. There was significantly less perception of pain with the DBS sampling method (P = 0.021). In conclusion, DBS analysis is a reliable alternative to venous blood sampling and can be used for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Patients were satisfied with DBS sampling and had less pain than with venous sampling. Most patients preferred DBS sampling to venous blood sampling.
Collapse
|
216
|
Pacini D, Cerana M, Beltrame A, Di Biagio A, De Maria A. Persistence ofCandida albicansCandidemia in Non-Neutropenic Surgical Patients: Management of a Representative Patient in the Absence of Second-Line Treatment Guidelines. J Chemother 2013; 19:335-8. [PMID: 17594931 DOI: 10.1179/joc.2007.19.3.335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Primary treatment failure and mortality in non-neutropenic patients with candidemia is high according to clinical trial experience. Current guidelines are mainly useful only for first line treatment strategies.We describe treatment failure and persistent protracted Candida albicans candidemia without clinically evident ocular involvement nor catheter recolonization in a malnourished non-neutropenic surgical patient with peritonitis. Primary antifungal treatment failure with fluconazole and secondary treatment failure with caspofungin occurred in the absence of evident Candida seeding the eye, valvular endocardium, or the intravascular catheter. Switch to liposomal amphotericin B was followed by clinical and microbiological cure. In patients with multiple risk factors for the acquisition of candidemia and life-threatening clinical conditions, the possibility of primary/secondary failure of new potent antifungal regimens may be initially neglected. Additional multicenter controlled clinical data are needed to guide the timing and choice of secondary antifungal treatment regimens in non-neutropenic candidemia patients.
Collapse
Affiliation(s)
- D Pacini
- Intensive Care Unit, Department of Accident and Emergency, University of Genoa, Genoa, Italy
| | | | | | | | | |
Collapse
|
217
|
Fanos V, Cuzzolin L, Atzei A, Testa M. Antibiotics and Antifungals in Neonatal Intensive Care Units: A Review. J Chemother 2013; 19:5-20. [PMID: 17309846 DOI: 10.1179/joc.2007.19.1.5] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The incidence of infections is higher in the neonatal period than at any time of life. The basic treatment of infants with infection has not changed substantially over the last years. Antibiotics (with or without supportive care) are one of the most valuable resources in managing sick newborn babies. Early-onset (ascending or transplacental) or late-onset (hospital acquired) infections present different chronology, epidemiology, physiology and outcome. Some classes of antibiotics are frequently used in the neonatal period: penicillins, cephalosporins, aminoglycosides, glycopeptides, monobactams, carbapenems. Other classes of antibiotics (chloramphenicol, cotrimoxazole, macrolides, clindamycin, rifampicin and metronidazole) are rarely used. Due to emergence of resistant bacterial strains in Neonatal Intensive Care Units (NICU), other classes of antibiotics such as quinolones and linezolid will probably increase their therapeutic role in the future. Although new formulations have been developed for treatment of fungal infections in infants, amphotericin B remains first-line treatment for systemic Candida infection. Prophylactic antibiotic therapy is almost always undesirable. Challenges from pathogens and antibiotic resistance in the NICU may warrant modification of traditional antibiotic regimens. Knowledge of local flora and practical application of different antibiotic characteristics are key to an effective and safe utilization of antibiotics and antifungals in critical newborns admitted to the NICU, and especially in very low birth weight infants.
Collapse
Affiliation(s)
- V Fanos
- Neonatal Intensive Care Unit - University of Cagliari, Italy.
| | | | | | | |
Collapse
|
218
|
Sánchez-Vargas LO, Estrada-Barraza D, Pozos-Guillen AJ, Rivas-Caceres R. Biofilm formation by oral clinical isolates of Candida species. Arch Oral Biol 2013; 58:1318-26. [PMID: 23849353 DOI: 10.1016/j.archoralbio.2013.06.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Revised: 05/08/2013] [Accepted: 06/05/2013] [Indexed: 11/18/2022]
Abstract
We have conducted a longitudinal study to quantify biofilms in oral clinical isolates of Candida species (spp.) from adults with local and systemic predisposing factors for candidiasis. A total of 69 yeast isolates from 63 Mexican patients were evaluated. These isolates (39 C. albicans, 15 C. tropicalis, 7 C. glabrata, 4 C. krusei, 1 C. lusitaniae, 1 C. kefyr, 1 C. guilliermondii and 1 C. pulcherrima) were obtained from two clinical sites: 62.3% (n=43) from the oral mucosa of totally and partially edentulous patients, and 37.7% (n=26) from the oral mucosa of diabetics. In addition, Candida ATCC strains were used as controls for each experiment. The kinetics of biofilm formation were measured by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide [XTT] reduction; each isolate was tested at 6, 12 and 24h. Biofilm formation is dependent on the Candida spp. and its clinical origin. On average, the oral isolates of C. glabrata are strong biofilm producers, whereas C. albicans and C. tropicalis are moderate producers. The most common species in our population was C. albicans. While the kinetics of C. albicans biofilm formation varies between oral isolates, it generally maintains steady growth from 2 to 48h, when it reaches its maximum growth.
Collapse
Affiliation(s)
- Luis Octavio Sánchez-Vargas
- Oral Microbiology, Pathology and Biochemical laboratory, Faculty of Stomatology, University Autonomous of San Luis Potosí, Mexico.
| | | | | | | |
Collapse
|
219
|
Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY 2013; 19:219-26. [PMID: 19412378 DOI: 10.1155/2008/161835] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2008] [Accepted: 02/27/2008] [Indexed: 11/18/2022]
Abstract
BACKGROUND Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia. METHODS A decision-analytical model was used for evaluating the cost-effectiveness of voriconazole compared with a regimen of conventional amphotericin B (CAB) followed by fluconazole (FLU) in the treatment of non-neutropenic patients diagnosed with candidemia in the Canadian setting, based on the Global Candidemia Study. The time frame of the model was 98 days (14 weeks). Model parameters were based primarily on clinical outcome, and resource use data collected from the clinical trial were used. Supplemental data were obtained from an independent panel of 12 Canadian experts for parameters not available from the clinical trial. Unit costs were collected from Canadian sources. The outcome variables selected in the study were the number of patients cured within 98 days, the number of patients surviving at 98 days and the number of patients avoiding toxicity. Incremental costs per outcome were calculated to compare the cost-effectiveness analyses (both probabilistic and one-way sensitivity analyses were performed). RESULTS The cost-effectiveness analysis demonstrated a difference of $1,121 in the total average cost of treatment with voriconazole ($70,489) versus CAB/FLU ($69,368). While the costs of voriconazole exceeded the costs of CAB/FLU, these costs were almost completely offset by lower hospitalization costs. While patients in both treatment arms experienced cure rates of 41%, both the percentage of patients surviving at day 98 (64.5% versus 58.2%) and the percentage of patients avoiding toxicity (64.5% versus 52.5%) were higher in the voriconazole arm. Accounting for differences in total costs and clinical outcomes, this analysis estimated an incremental cost per patient surviving at day 98 of $17,739, and an incremental cost per patient avoiding toxicity of $9,298. In the case of cost per patient cured, voriconazole had a higher cost ($1,121) than CAB/FLU. The results of the deterministic and probabilistic sensitivity analyses indicated that the model was robust. CONCLUSIONS Results of the decision-analytical model provided evidence to support the cost-effectiveness of voriconazole relative to a regimen of CAB/FLU in the treatment of non-neutropenic patients diagnosed with candidemia in the Canadian setting.
Collapse
|
220
|
Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi IN, Cortes JA, Echevarría J, Sifuentes J, Zurita J, Santolaya ME, Alvarado Matute T, de Queiroz Telles F, Colombo AL. Recommendations for the management of candidemia in adults in Latin America. Rev Iberoam Micol 2013; 30:179-88. [DOI: 10.1016/j.riam.2013.05.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 05/09/2013] [Accepted: 05/16/2013] [Indexed: 02/01/2023] Open
|
221
|
Osawa K, Shigemura K, Yoshida H, Fujisawa M, Arakawa S. Candida urinary tract infection and Candida species susceptibilities to antifungal agents. J Antibiot (Tokyo) 2013; 66:651-4. [PMID: 23801184 DOI: 10.1038/ja.2013.68] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2013] [Revised: 05/20/2013] [Accepted: 05/29/2013] [Indexed: 11/09/2022]
Abstract
The purpose of this study is to review Candida isolation from urine of urinary tract infection (UTI) patients over the recent 3 years at the Kobe University Hospital. We recorded the type of strain, the department where the patient was treated such as the intensive care unit (ICU), and combined isolation of Candida with other microorganisms. We investigated Candida isolation and susceptibilities to antifungal agents and analyzed the risk factors for combined isolation with other microorganisms. The most frequently isolated Candida was Candida albicans, which showed good (100%) susceptibilities to 5-fluorocytosine (5-FC) and fluconazole (FLCZ) but not to voriconazole (VRCZ), followed by C. glabrata. ICU was the greatest source of Candida-positive samples, and the most relevant underlying diseases of ICU patients were pneumonia followed by renal failure and post liver transplantation status. Combined isolation with other bacteria was seen in 27 cases (42.9%) in 2009, 25 (33.3%) in 2010 and 31 (31.3%) in 2011 and comparatively often seen in non-ICU patients. Other candidas than C. albicans showed significantly decreased susceptibility to FLCZ over these 3 years (P=0.004). One hundred (97.1%) of 103 ICU cases were given antibiotics at the time of Candida isolation, and the most often used antibiotics were cefazolin or meropenem. In conclusion, C. albicans was representatively isolated in Candida UTI and showed good susceptibilities to 5-FC, FLCZ and VRCZ, but other candidas than C. albicans showed significantly decreased susceptibility to FLCZ in the change of these 3 years.
Collapse
Affiliation(s)
- Kayo Osawa
- Infectious control team, Kobe University Hospital, Kobe, Japan
| | | | | | | | | |
Collapse
|
222
|
Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BIOMED RESEARCH INTERNATIONAL 2013; 2013:204237. [PMID: 23878798 PMCID: PMC3708393 DOI: 10.1155/2013/204237] [Citation(s) in RCA: 188] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Revised: 06/06/2013] [Accepted: 06/06/2013] [Indexed: 11/25/2022]
Abstract
The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive. Superficial infections often affect the skin or mucous membranes and can be treated successfully with topical antifungal drugs. However, invasive fungal infections are often life-threatening, probably due to inefficient diagnostic methods and inappropriate initial antifungal therapies. Here, we briefly review our current knowledge of pathogenic species of the genus Candida and yeast infection causes and then focus on current antifungal drugs and resistance mechanisms. An overview of new therapeutic alternatives for the treatment of Candida infections is also provided.
Collapse
Affiliation(s)
- Claudia Spampinato
- Departamento de Química Biológica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina
- Centro de Estudios Fotosintéticos y Bioquímicos (CEFOBI, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina
| | - Darío Leonardi
- Departamento de Tecnología Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina
- Instituto de Química Rosario (IQUIR, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina
| |
Collapse
|
223
|
Filler SG. Can host receptors for fungi be targeted for treatment of fungal infections? Trends Microbiol 2013; 21:389-96. [PMID: 23796589 DOI: 10.1016/j.tim.2013.05.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Revised: 05/23/2013] [Accepted: 05/24/2013] [Indexed: 11/19/2022]
Abstract
The invasion and stimulation of normally non-phagocytic host cells, such as epithelial and endothelial cells, is a key step in the pathogenesis of many fungal infections. In most cases, host cell invasion and/or stimulation of a proinflammatory response is induced when proteins or carbohydrates on the fungal cell surface bind to receptors on the host cell. Although many of these fungal-host cell interactions have only been investigated in vitro, the therapeutic efficacy of blocking the host cell receptors for Candida albicans and Rhizopus oryzae has been demonstrated in experimental animal models of infection. We summarize recent studies of the fungal receptors on normally non-phagocytic host cells and the therapeutic implications of blocking these receptors.
Collapse
Affiliation(s)
- Scott G Filler
- Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA.
| |
Collapse
|
224
|
Abstract
Invasive fungal infections, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to their associated high morbidity, mortality rate, increased incidence, and healthcare costs. For these reasons, new studies and laboratory tests have been developed over the last few years in order to formulate an early therapeutic intervention strategy in an attempt to reduce the high mortality rate associated with these infections. In recent years, evidence-based studies have shown the roles that the new antifungal drugs play in the treatment of invasive mycosis in seriously ill and complex patients, although data from critically ill patients are more limited. New antifungal agents have been analyzed in different clinical situations in critical care units, and the increasing number of non-Candida albicans species suggest that the application of early echinocandin therapy in critically ill patients with invasive candidiasis is a good option. Voriconazole should be recommended for invasive aspergillosis as a first line option.
Collapse
|
225
|
Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi IN, Cortes JA, Echevarría J, Sifuentes J, Zurita J, Santolaya ME, Alvarado Matute T, de Queiroz Telles F, Colombo AL. [Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Épico]. Rev Iberoam Micol 2013; 30:179-88. [PMID: 23764556 DOI: 10.1016/j.riam.2013.06.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 05/16/2013] [Indexed: 01/23/2023] Open
Abstract
Candidemia is one of the most frequent opportunistic mycoses worldwide. Limited epidemiological studies in Latin America indicate that incidence rates are higher in this region than in the Northern Hemisphere. Diagnosis is often made late in the infection, affecting the initiation of antifungal therapy. A more scientific approach, based on specific parameters, for diagnosis and management of candidemia in Latin America is warranted. 'Recommendations for the diagnosis and management of candidemia' are a series of manuscripts that have been developed by members of the Latin America Invasive Mycosis Network. They aim to provide a set of best-evidence recommendations for the diagnosis and management of candidemia. This publication, 'Recommendations for the management of candidemia in adults in Latin America', was written to provide guidance to healthcare professionals on the management of adults who have, or who are at risk of, candidemia. Computerized searches of existing literature were performed by PubMed. The data were extensively reviewed and analyzed by members of the group. The group also met on two occasions to pose questions, discuss conflicting views, and deliberate on a series of management recommendations. 'Recommendations for the management of candidemia in adults in Latin America' includes prophylaxis, empirical therapy, therapy for proven candidemia, patient work-up following diagnosis of candidemia, duration of candidemia treatment, and central venous catheter management in patients with candidemia. This manuscript is the second of this series that deals with diagnosis and treatment of invasive candidiasis. Other publications in this series include: 'Recommendations for the diagnosis of candidemia in Latin America', 'Recommendations for the management of candidemia in children in Latin America', and 'Recommendations for the management of candidemia in neonates in Latin America'.
Collapse
Affiliation(s)
- Marcio Nucci
- Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Latin America Invasive Mycosis Network.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
226
|
Silva NC, Nery JM, Dias ALT. Aspartic proteinases of Candida spp.: role in pathogenicity and antifungal resistance. Mycoses 2013; 57:1-11. [PMID: 23735296 DOI: 10.1111/myc.12095] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2013] [Revised: 05/03/2013] [Accepted: 05/08/2013] [Indexed: 12/20/2022]
Abstract
Fungal infections represent a serious health risk as they are particularly prevalent in immunocompromised individuals. Candida spp. pathogenicity depends on several factors and secreted aspartic proteinases (Sap) are considered one of the most critical factors as they are associated with adhesion, invasion and tissue damage. The production of proteinases is encoded by a family of 10 genes known as SAP, which are distributed differently among the species. The expression of these genes may be influenced by environmental conditions, which generally result in a higher fungal invasive potential. Non-pathogenic Candida spp. usually have fewer SAP genes, which are not necessarily expressed in the genome. Exposure to subinhibitory concentrations of antifungal agents promotes the development of resistant strains with an increased expression of SAP genes. In general, Candida spp. isolates that are resistant to antifungals show a higher secretion of Sap than the susceptible isolates. The relationship between Sap secretion and the susceptibility profile of the isolates is of great interest, although the role of SAPs in the development of resistance to antifungal agents remains still unclear. This review is the first one to address these issues.
Collapse
Affiliation(s)
- Naiara C Silva
- Microbiology and Immunology Department, Federal University of Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil
| | | | | |
Collapse
|
227
|
Chahoud J, Kanafani ZA, Kanj SS. Management of candidaemia and invasive candidiasis in critically ill patients. Int J Antimicrob Agents 2013; 42 Suppl:S29-35. [PMID: 23664579 DOI: 10.1016/j.ijantimicag.2013.04.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Critically ill patients in the intensive care unit (ICU) are at increased risk of encountering bloodstream infections (BSIs) with Candida spp., associated with an elevated crude mortality rate. This supports the significance of early detection of infection and identification of the most effective management approach. A review of the various antifungal treatments and an evaluation of the diverse management approaches for invasive candidiasis in critically ill patients is necessary for guiding evidence-based decision-making. Different early detection schemes for invasive candidiasis are well documented in the literature. Other than the common use of blood cultures, new methods entail the use of risk prediction scores and biomarker tests. Regarding management strategies, different options are currently supported. These include prophylaxis, empirical therapy, pre-emptive therapy, and treatment of culture-documented infections. The choice of treatment is greatly dependent on several factors related to the patient and/or to the surrounding environment. Attention needs to be given to previous exposure to azoles, epidemiological data on dominant Candida spp. in local ICUs, severity of illness and associated morbidities. This paper summarises the most recent literature as well as the guidelines issued by the Infectious Diseases Society of America. The objective is to identify the best diagnosis and management approaches for serious Candida infections in critically ill patients. In addition, this article addresses an important aspect associated with managing candidaemia in critically ill patients pertaining to the decision for intravenous catheter removal.
Collapse
Affiliation(s)
- Jad Chahoud
- Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Cairo Street P.O. Box 11-0236/11D, Riad El-Solh 1107 2020, Beirut, Lebanon
| | | | | |
Collapse
|
228
|
Gao Y, Zhang C, Lu C, Liu P, Li Y, Li H, Sun S. Synergistic effect of doxycycline and fluconazole againstCandida albicansbiofilms and the impact of calcium channel blockers. FEMS Yeast Res 2013; 13:453-62. [PMID: 23577622 DOI: 10.1111/1567-1364.12048] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 03/25/2013] [Accepted: 04/05/2013] [Indexed: 11/28/2022] Open
Affiliation(s)
- Yuan Gao
- School of Pharmaceutical Sciences; Shandong University; Jinan; Shandong Province; China
| | - Caiqing Zhang
- Department of Respiratory Medicine; Shandong Provincial Qianfoshan Hospital; Jinan; Shandong Province; China
| | - Chunyan Lu
- Department of Pharmacy; Shandong Provincial Qianfoshan Hospital; Jinan; Shandong Province; China
| | - Ping Liu
- School of Pharmaceutical Sciences; Shandong University; Jinan; Shandong Province; China
| | - Yan Li
- Department of Oncology; Shandong Provincial Qianfoshan Hospital; Jinan; Shandong Province; China
| | - Hui Li
- School of Pharmaceutical Sciences; Shandong University; Jinan; Shandong Province; China
| | - Shujuan Sun
- Department of Pharmacy; Shandong Provincial Qianfoshan Hospital; Jinan; Shandong Province; China
| |
Collapse
|
229
|
Abstract
BACKGROUND Candida is the third most common cause of late-onset neonatal sepsis in infants born at <1500 g. Candida parapsilosis infections are increasingly reported in preterm neonates in association with indwelling catheters. METHODS We systematically reviewed neonatal literature and synthesized data pertaining to percentage of C. parapsilosis infections and mortality by meta-analyses. We also reviewed risk factors, virulence determinants, antimicrobial susceptibility patterns and outlined clinical management strategies. RESULTS C. parapsilosis infections comprised 33.47% (95% confidence interval [CI]: 30.02, 37.31) of all neonatal Candida infections. C. parapsilosis rates were similar in studies performed before the year 2000, 33.53% (95% CI: 30.06, 37.40) (28 studies), to those after 2000, 27.00% (95% CI: 8.25, 88.37) (8 studies). The mortality due to neonatal C. parapsilosis infections was 10.02% (95% CI: 7.66, 13.12). Geographical variations in C. parapsilosis infections included a low incidence in Europe and higher incidence in North America and Australia. Biofilm formation was a significant virulence determinant and predominant risk factors for C. parapsilosis infections were prematurity, prior colonization and catheterization. Amphotericin B remains the antifungal drug of choice and combination therapy with caspofungin or other echinocandins may be considered in resistant cases. CONCLUSION C. parapsilosis is a significant neonatal pathogen, comprises a third of all Candida infections and is associated with 10% mortality. Availability of tools for genetic manipulation of this organism will identify virulence determinants and organism characteristics that may explain predilection for preterm neonates. Strategies to prevent horizontal transmission in the neonatal unit are paramount in decreasing infection rates.
Collapse
|
230
|
Evans D, Maskew M, Sanne I. Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 113:362-72. [PMID: 22669142 DOI: 10.1016/j.oooo.2011.09.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 09/02/2011] [Accepted: 09/07/2011] [Indexed: 11/30/2022]
Abstract
OBJECTIVE We investigated the effect of oropharyngeal candidiasis (OC) and body mass index (BMI) before antiretroviral therapy (ART) initiation on treatment outcomes of human immunodeficiency virus (HIV)-positive patients. STUDY DESIGN Treatment outcomes included failure to increase CD4 count by ≥50 or ≥100 cells/μL or failure to suppress viral load (<400 copies/mL) at 6 or 12 months in addition to loss to follow-up (LTFU) and mortality by 12 months. Risk and hazard ratios (HRs) were estimated with the use of log-binomial regression and Cox proportional hazards models, respectively. RESULTS Baseline CD4 <100 cells/μL, low BMI (<18.5 kg/m(2)), low hemoglobin, and elevated aspartate transaminase were associated with OC at ART initiation. Patients with low BMI with and without, respectively, OC were at risk of mortality (HR 2.42, 95% CI 1.88-3.12; HR 1.87, 95% CI 1.54-2.28) and LTFU (HR 1.36, 95% CI 1.02-1.82; HR 1.55, 95% CI 1.30-1.85). CONCLUSIONS Low BMI (with/without OC) at ART initiation was associated with poor treatment outcomes. Conversely, normal BMI with OC was associated with adequate CD4 response and reduced LTFU compared with without OC.
Collapse
Affiliation(s)
- Denise Evans
- Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | | | | |
Collapse
|
231
|
Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wellman P, Mylonakis E, Lowery TJ. T2 Magnetic Resonance Enables Nanoparticle-Mediated Rapid Detection of Candidemia in Whole Blood. Sci Transl Med 2013; 5:182ra54. [DOI: 10.1126/scitranslmed.3005377] [Citation(s) in RCA: 205] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
232
|
Cecinati V, Guastadisegni C, Russo FG, Brescia LP. Antifungal therapy in children: an update. Eur J Pediatr 2013; 172:437-46. [PMID: 22652706 DOI: 10.1007/s00431-012-1758-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Accepted: 05/09/2012] [Indexed: 10/28/2022]
Abstract
Invasive fungal infections are a common problem in children affected by primary or secondary immunodeficiencies. Thanks to an increased knowledge about their mechanisms of action and their pharmacokinetic and toxicity profiles, the use of these drugs in common and uncommon invasive infections in immunocompromised children has improved over the last decades. Choosing the most appropriate antifungal drug is a serious challenge for any clinician, also considering that, in most cases, therapy has to be started before cultures are available, the choice being driven by clinical symptoms and statistical criteria only. In this study, we performed a systematic review of literature, providing antifungal treatment recommendations for paediatric patients which can help clinicians find the most suitable treatment for each specific case. Principal antifungal drugs-ranging from first-generation antimycotics to the latest molecules-are classified according to their targets, and of each group, the pharmacokinetic profile, clinical indications and side effects are extensively described.
Collapse
Affiliation(s)
- Valerio Cecinati
- Division of Pediatric Hematology and Oncology, Department of Hematology, Spirito Santo Hospital, Via Fonte Romana, Pescara, Italy.
| | | | | | | |
Collapse
|
233
|
Scorzoni L, de Lucas MP, Mesa-Arango AC, Fusco-Almeida AM, Lozano E, Cuenca-Estrella M, Mendes-Giannini MJ, Zaragoza O. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile. PLoS One 2013; 8:e60047. [PMID: 23555877 PMCID: PMC3610750 DOI: 10.1371/journal.pone.0060047] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Accepted: 02/20/2013] [Indexed: 12/28/2022] Open
Abstract
The incidence of opportunistic fungal infections has increased in recent decades due to the growing proportion of immunocompromised patients in our society. Candida krusei has been described as a causative agent of disseminated fungal infections in susceptible patients. Although its prevalence remains low among yeast infections (2-5%), its intrinsic resistance to fluconazole makes this yeast important from epidemiologic aspects. Non mammalian organisms are feasible models to study fungal virulence and drug efficacy. In this work we have used the lepidopteran Galleria mellonella and the nematode Caenorhabditis elegans as models to assess antifungal efficacy during infection by C. krusei. This yeast killed G. mellonella at 25, 30 and 37°C and reduced haemocytic density. Infected larvae melanized in a dose-dependent manner. Fluconazole did not protect against C. krusei infection, in contrast to amphotericin B, voriconazole or caspofungin. However, the doses of these antifungals required to obtain larvae protection were always higher during C. krusei infection than during C. albicans infection. Similar results were found in the model host C. elegans. Our work demonstrates that non mammalian models are useful tools to investigate in vivo antifungal efficacy and virulence of C. krusei.
Collapse
Affiliation(s)
- Liliana Scorzoni
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
- Laboratório de Micologia Clínica, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista de São Paulo, Araraquara, Brazil
| | - Maria Pilar de Lucas
- Department of Cellular Biology, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Ana Cecilia Mesa-Arango
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
- Group of Investigative Dermatology, University of Antioquia, Medellín, Colombia
| | - Ana Marisa Fusco-Almeida
- Laboratório de Micologia Clínica, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista de São Paulo, Araraquara, Brazil
| | - Encarnación Lozano
- Department of Cellular Biology, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Manuel Cuenca-Estrella
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Maria Jose Mendes-Giannini
- Laboratório de Micologia Clínica, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista de São Paulo, Araraquara, Brazil
- * E-mail: (MJMG); (OZ)
| | - Oscar Zaragoza
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
- * E-mail: (MJMG); (OZ)
| |
Collapse
|
234
|
Amri Saroukolaei S, Pei Pei C, Shokri H, Asadi F. Purification and comparison of intracellular proteinase A in Candida spp. isolates from Malaysian and Iranian patients and infected mice. J Mycol Med 2013; 22:149-59. [PMID: 23518017 DOI: 10.1016/j.mycmed.2012.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Revised: 12/20/2011] [Accepted: 01/05/2012] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To compare the specific intracellular proteinase A activity in clinical isolates of Candida species isolated from Iranian and Malaysian patients, the blood and kidneys of mice infected by Candida cells isolated from these human patients. PATIENTS AND METHODS The intracellular proteinase A was extracted using glass beads and ultracentrifugation from yeasts cells and purified by ion-exchange chromatography (DEAE-cellulose), followed by affinity chromatography (ConA-agarose). Purity of proteinase A was controlled by SDS-PAGE and its identification was realized by western blot. Enzyme activity was performed using azocasein as substrate. RESULTS Intracellular proteinase A enzyme activity was higher in Candida albicans (C. albicans) than in non-albicans Candida isolates from Malaysian and Iranian patients, mice blood and mice kidneys (P<0.05). In clinical Candida spp. from human patients, proteinase A activity was significantly higher in Malaysian samples than in their Iranian counterparts (P<0.05). However, Candida spp. isolates obtained from blood and kidneys of mice infected by human clinical strains of Candida spp. showed no significant differences in proteinase A activity between Malaysian and Iranian samples (P>0.05). On the other hand, in both clinical and control yeast isolates obtained from Malaysian and Iranian patients, significant differences were found between systemic and non-systemic samples (P<0.05) but this difference was not observed in mice blood and kidneys. CONCLUSION In the present study, a strong proteinase A activity was observed for C. albicans and higher expression of this enzyme in clinical isolates from Malaysian and Iranian patients with systemic candidiasis indicated higher virulent nature of this yeast species when compared with non-albicans Candida strains.
Collapse
Affiliation(s)
- S Amri Saroukolaei
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Selangor, Malaysia
| | | | | | | |
Collapse
|
235
|
Turner K, Manzoni P, Benjamin DK, Cohen-Wolkowiez M, Smith PB, Laughon MM. Fluconazole pharmacokinetics and safety in premature infants. Curr Med Chem 2013; 19:4617-20. [PMID: 22876898 DOI: 10.2174/092986712803306367] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Revised: 01/13/2012] [Accepted: 01/15/2012] [Indexed: 11/22/2022]
Abstract
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these data, a treatment dose of 12 mg/kg/day, with the potential need of a loading dose of 25 mg/kg to achieve rapid steady state concentrations, achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal reversible hepatobiliary effects.
Collapse
Affiliation(s)
- K Turner
- Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | | | | | | | | | | |
Collapse
|
236
|
Parasuraman R, Julian K. Urinary tract infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:327-36. [PMID: 23465025 DOI: 10.1111/ajt.12124] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- R Parasuraman
- Division of Nephrology and Transplantation, Oakland University William Beaumont School of Medicine, Beaumont Health System, Royal Oak, MI, USA.
| | | | | |
Collapse
|
237
|
de-Oliveira AP, de-Oliveira RP, Gaspar C, Salgueiro L, Cavaleiro C, de-Oliveira JM, Queiroz J, Rodrigues A. Association ofThymbra capitataessential oil and chitosan (TCCH hydrogel): a putative therapeutic tool for the treatment of vulvovaginal candidosis. FLAVOUR FRAG J 2013. [DOI: 10.1002/ffj.3144] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Palmeira- de-Oliveira
- CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences; University of Beira Interior; Covilhã; Portugal
| | - R. Palmeira- de-Oliveira
- CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences; University of Beira Interior; Covilhã; Portugal
| | - C. Gaspar
- CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences; University of Beira Interior; Covilhã; Portugal
| | - L. Salgueiro
- Center of Pharmaceutical Studies, Faculty of Pharmacy; University of Coimbra; Portugal
| | - C. Cavaleiro
- Center of Pharmaceutical Studies, Faculty of Pharmacy; University of Coimbra; Portugal
| | | | - J.A. Queiroz
- CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences; University of Beira Interior; Covilhã; Portugal
| | | |
Collapse
|
238
|
Rapid and accurate identification of isolates of Candida species by melting peak and melting curve analysis of the internally transcribed spacer region 2 fragment (ITS2-MCA). Res Microbiol 2013; 164:110-7. [DOI: 10.1016/j.resmic.2012.10.017] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 10/15/2012] [Indexed: 11/23/2022]
|
239
|
Deelstra JJ, Neut D, Jutte PC. Successful treatment of Candida albicans-infected total hip prosthesis with staged procedure using an antifungal-loaded cement spacer. J Arthroplasty 2013; 28:374.e5-8. [PMID: 22810009 DOI: 10.1016/j.arth.2012.04.034] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 03/13/2012] [Accepted: 04/23/2012] [Indexed: 02/01/2023] Open
Abstract
We present a rare case of an immunocompetent host who developed a Candida albicans-infected total hip prosthesis. The infection could not be eradicated with debridement and extensive antifungal therapy. Our patient first underwent a resection of the proximal femur and local treatment with gentamicin-loaded cement beads. In a second procedure, a handmade cement spacer impregnated with voriconazole, amphotericin B, and vancomycin was placed. After 3 months of additional systemic antibiotic therapy, the patient remained afebrile, and a tumor prosthesis was placed. Six years postoperatively, she is doing well, walking with a small limp and no signs of recurrent infection. This is the first report on elution of voriconazole and amphotericin B from bone cement delivered at clinically significant concentrations for at least 72 hours.
Collapse
Affiliation(s)
- Jenneke J Deelstra
- Department of Orthopedic Surgery, University Medical Center Groningen, The Netherlands
| | | | | |
Collapse
|
240
|
Zhang J, Liu W, Tan J, Sun Y, Wan Z, Li R. Antifungal Activity of Geldanamycin Alone or in Combination with Fluconazole Against Candida species. Mycopathologia 2013; 175:273-9. [DOI: 10.1007/s11046-012-9612-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Accepted: 12/26/2012] [Indexed: 01/15/2023]
|
241
|
Kaplancikli ZA, Yurttaş L, Özdemir A, Turan-Zitouni G, Işcan G, Akalın G, Abu Mohsen U. Synthesis, anticandidal activity and cytotoxicity of some tetrazole derivatives. J Enzyme Inhib Med Chem 2013; 29:43-8. [PMID: 23323990 DOI: 10.3109/14756366.2012.752363] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In this study, 14 different 2-[(1-methyl-1H-tetrazole-5-yl)thio]-1-(phenyl)ethanone derivatives (1-14) were synthesized. The structures of the obtained compounds were elucidated using IR, (1)H-NMR, (13)C-NMR and FAB(+)-MS spectral data and elemental analyses results. The compounds were screened for their anticandidal activity using the microbroth dilution method and for their cytotoxic effects using the MTT assay against NIH/3T3 cells. Some of the compounds were found to be potent anticandidal agents with weak cytotoxicities.
Collapse
Affiliation(s)
- Zafer Asim Kaplancikli
- Department of Pharmaceutical Chemistry, Graduate School of Health Sciences, Anadolu University , Eskisehir , Turkey
| | | | | | | | | | | | | |
Collapse
|
242
|
Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother 2013; 57:1918-20. [PMID: 23318790 DOI: 10.1128/aac.02378-12] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Candida biofilm infections pose an increasing threat in the health care setting due to the drug resistance associated with this lifestyle. Several mechanisms underlie the resistance phenomenon. In Candida albicans, one mechanism involves drug impedance by the biofilm matrix linked to β-1,3 glucan. Here, we show this is important for other Candida spp. We identified β-1,3 glucan in the matrix, found that the matrix sequesters antifungal drug, and enhanced antifungal susceptibility with matrix β-1,3 glucan hydrolysis.
Collapse
|
243
|
Pandolfini C, Marco S, Paolo M, Maurizio B. The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey. BMC Pediatr 2013; 13:5. [PMID: 23294560 PMCID: PMC3546886 DOI: 10.1186/1471-2431-13-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Accepted: 12/28/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Treatment and prophylaxis of sepsis in very low birth weight neonates is a matter of concern and research is being undertaken with the aim to give rise to shared approaches based on solid evidence. As part of a European initiative, a survey was set up to describe the use of two drugs in this area. The Italian national practices concerning neonatal sepsis, as well as calls for related guidance, are described. METHODS A standardized and previously tested questionnaire was submitted online to all Italian level III NICUs. A 5-point Likert scale was used to analyze attitudinal replies. Categorical variables were compared by χ2 analysis and 2-tailed P-values are reported. RESULTS Data was provided by 38 Italian NICUs (36% of the country's level III centers), 53% of which have 1-10 cases of bacterial sepsis monthly and 90% a prevalence of <1% fungal infections. Ciprofloxacin and fluconazole treatment for neonatal sepsis are scantly used in Italian NICUs (13% and 45%, respectively). Major concerns are related to the safety of ciprofloxacin and the efficacy of fluconazole. On the contrary, prophylaxis of fungal infections is a routine approach in many Italian NICUs. The use of both ciprofloxacin and fluconazole is characterized by a large inter-NICU variability in dose and scheme of use. The lack of adequate, shared evidence is a common consideration made by the survey participants. CONCLUSIONS Common approaches are needed to standardize and update a national drug strategy for the prevention and treatment of sepsis in very low birth weight newborns. This can be achieved through collaborative initiatives aimed at setting up guidelines, based on available data, and multicenter trials to produce new evidence that will address the knowledge gaps.
Collapse
Affiliation(s)
- Chiara Pandolfini
- Laboratory for Mother and Child Health, Department of Public Health “Mario Negri” Pharmacological Research Institute, Milan, Italy
| | - Sequi Marco
- Laboratory for Mother and Child Health, Department of Public Health “Mario Negri” Pharmacological Research Institute, Milan, Italy
| | - Manzoni Paolo
- Neonatology and Hospital Neonatal Intensive Care Unit, Azienda Ospedaliera Regina Margherita – Sant’Anna, Turin, Italy
| | - Bonati Maurizio
- Laboratory for Mother and Child Health, Department of Public Health “Mario Negri” Pharmacological Research Institute, Milan, Italy
| |
Collapse
|
244
|
Giri S, Kindo AJ. A review of Candida species causing blood stream infection. Indian J Med Microbiol 2013; 30:270-8. [PMID: 22885191 DOI: 10.4103/0255-0857.99484] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The incidence of candidemia has been on a rise worldwide. The epidemiology of invasive fungal infections in general and of candidemia in particular has changed in the past three decades because of a variety of factors like the AIDS epidemic, increased number of patients receiving immunosuppressive therapy for transplantation and the increasing use of antimicrobials in the hospital setups and even in the community. The important risk factors for candidemia include use of broad-spectrum antimicrobials, cancer chemotherapy, mucosal colonization by Candida species, indwelling vascular catheters like central venous catheters, etc. More than 90% of the invasive infections due to Candida species are attributed to five species-Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei. However, the list of new species of Candida isolated from clinical specimens continues to grow every year. Early diagnosis and proper treatment is the key for management of candidemia cases.
Collapse
Affiliation(s)
- S Giri
- Department of Microbiology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India
| | | |
Collapse
|
245
|
López-Medrano F, Juan RS, Lizasoain M, Catalán M, Ferrari J, Chaves F, Lumbreras C, Montejo J, de Tejada AH, Aguado J. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19:56-61. [DOI: 10.1111/j.1469-0691.2012.03891.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
246
|
|
247
|
Ullmann A, Cornely O, DonneNy J, Akova M, Arendrup M, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Garbino J, Groll A, Herbrecht R, Hope W, Jensen H, Kullberg B, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson M, Roilides E, Verweij P, Viscoli C, Cuenca-Estrella M. ESCMID* *Information in this manuscript was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012; 18 Suppl 7:1-8. [DOI: 10.1111/1469-0691.12037] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
248
|
Lai YC, Huang LJ, Chen TL, Yang YW, Hsiao LT, Teng HW, Fung CP, Chiou TJ, Tzeng CH, Liu CY. Impact of Port-A-Cath device management in cancer patients with candidaemia. J Hosp Infect 2012; 82:281-5. [DOI: 10.1016/j.jhin.2012.08.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2011] [Accepted: 08/22/2012] [Indexed: 11/26/2022]
|
249
|
Agustí G, Fittipaldi M, Morató J, Codony F. Viable quantitative PCR for assessing the response of Candida albicans to antifungal treatment. Appl Microbiol Biotechnol 2012; 97:341-9. [DOI: 10.1007/s00253-012-4524-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2012] [Revised: 10/15/2012] [Accepted: 10/19/2012] [Indexed: 11/28/2022]
|
250
|
Elsayed H, Shaker H, Whittle I, Hussein S. The impact of systemic fungal infection in patients with perforated oesophagus. Ann R Coll Surg Engl 2012; 94:579-84. [PMID: 23131229 PMCID: PMC3954285 DOI: 10.1308/003588412x13373405388095] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/06/2012] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Perforated oesophagus is a surgical emergency with significant morbidity and mortality. Systemic fungal infection represents a poor response to the magnitude of the insult, which adds significantly to the risk of morbidity and mortality in these patients. We reviewed our experience with this group of patients over a six-year period in a tertiary referral centre. METHODS A retrospective clinical review was conducted of patients who were admitted following a ruptured oesophagus over a period of six years (January 2002 - January 2008). RESULTS We had 27 admissions (18 men and 9 women) following an isolated perforated oesophagus to our unit. The median patient age was 65 years (range: 22-87 years). The majority (n=24, 89%) presented with spontaneous perforations (Boerhaave's syndrome) and three (11%) were iatrogenic. Fungal organisms, predominantly Candida albicans, were positively cultured in pleural or blood samples in 16 (59%) of the 27 patients. Fourteen patients grew yeasts within the first seven days while two showed a delayed growth after ten days. Overall mortality was 5 out of 27 patients (19%). There was no mortality among the group that did not grow yeasts in their blood/pleural fluid while mortality was 31% (5/16) in the group with systemic fungal infection (p<0.001). A positive fungal culture was also associated with increase ventilation time, intensive care unit stay and inpatient hospital stay but not an increased rate of complications. CONCLUSIONS Systemic fungal infection in patients with a ruptured oesophagus affects a significant proportion of these patients and carries a poor prognosis despite advanced critical care interventions. It may represent a general marker of poor host response to a major insult but can add to mortality and morbidity. It is worth considering adding antifungal therapy empirically at an early stage to antimicrobials in patients with an established diagnosis of a perforated oesophagus.
Collapse
Affiliation(s)
- H Elsayed
- Liverpool Heart and Chest Hospital NHS Foundation Trust, UK.
| | | | | | | |
Collapse
|